TSE:APHA

Aphria - APHA Stock Forecast, Price & News

C$16.55

-0.98 (-5.59%)

(As of 05/4/2021)

Add

Compare

Today's Range: C$16.41
▼
C$17.52
50-Day Range: C$16.55
▼
C$16.55
52-Week Range: C$3.93
▼
C$40.93

Volume: 9.61 million shs
Average Volume: 6.16 million shs
Market Capitalization: C$5.24 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Aphria (TSE:APHA) Stock

Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.

Receive APHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aphria and its competitors with MarketBeat's FREE daily newsletter.

APHA Stock News Headlines

October 7, 2022 | finance.yahoo.com

Global Legal Cannabis Market Report 2022-2030 Featuring Gw Pharmaceuticals, Aurora, Aphria, Cronos, Tilray, Sundial Growers, Insys Therapeutics, Scotts Co, Vivo Cannabis, & Cara Therapeutics - Yahoo Finance

October 1, 2022 | benzinga.com

Global Cannabis Extract Market to Reach $15.5 Billion by 2030 at a CAGR of 20.6% - Benzinga

March 21, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

September 30, 2022 | globenewswire.com

Global Medical Marijuana Market Report 2022-2030: Surge in the Number of Countries Legalizing the Usage of Medical Marijuana - GlobeNewswire

September 26, 2022 | globenewswire.com

Global Legal Cannabis Market Analysis Report 2022: A $134.4 Billion Industry by 2030, Growing at a CAGR of Over 25% - GlobeNewswire

September 21, 2022 | globenewswire.com

Global Cannabis Extract Market Report 2022: Elimination of the Black Market Through the Legalization of Medical Cannabis Drives Growth - GlobeNewswire

September 8, 2022 | investing.com

Tilray Simply Needs To Do Better | investing.com - Investing.com

September 1, 2022 | seekingalpha.com

Tilray Brands: No One Is Happy (NASDAQ:TLRY) - Seeking Alpha

March 21, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

August 30, 2022 | theglobeandmail.com

Cannabis producer Tilray lays off at least 22 migrant farm workers - The Globe and Mail

August 25, 2022 | globenewswire.com

Tilray Medical Launches New Products and 'CannaPoints' - GlobeNewswire

August 16, 2022 | businesswire.com

North America Legal Marijuana Market Size, Share & Trends Analysis Report 2022-2030 - ResearchAndMarkets.com - Business Wire

August 2, 2022 | benzinga.com

Canopy Growth Taps Ex Aphria Executive Christelle Gedeon As New Chief Legal Officer - Benzinga

July 25, 2022 | fool.ca

3 Stocks That Have Flopped Hard This Year - The Motley Fool Canada

June 25, 2022 | nasdaq.com

5 Growth Stocks to Buy for 5-Bagger Returns in 5 Years - Nasdaq

June 22, 2022 | streetinsider.com

Tilray Medical Welcomes Government of Luxembourg Delegation Visit to European Campus in Portugal - StreetInsider.com

June 13, 2022 | forbes.com

A Sneak Preview Of Diplo And Rob Dyrdek’s New Cannabis Seltzers, Leisuretown - Forbes

May 17, 2022 | seekingalpha.com

Tilray Brands: Almost Good Enough - Seeking Alpha

May 12, 2022 | fool.com

Down 80% From Its High, Can Tilray Stock Spark Again? - The Motley Fool

April 14, 2022 | thestreet.com

Tilray Stock: Experts Forecast More Than 20% Upside Potential - TheStreet

April 5, 2022 | fool.com

3 Huge Things to Watch in Tilray's Q3 Earnings Report This Week - The Motley Fool

March 25, 2022 | thestreet.com

With Marijuana Legalization In Sight, Tilray Stock Could Be A Major Beneficiary - TheStreet

March 13, 2022 | fool.com

Is Tilray Making a Colossal Mistake? - The Motley Fool

January 14, 2022 | investorplace.com

Why Tilray Stock Is Starting to Look Interesting - InvestorPlace

January 6, 2022 | 247wallst.com

Earnings Previews: Albertsons, Commercial Metals, Tilray - 24/7 Wall St.

January 4, 2022 | investorplace.com

Tilray Isn't Your Cannabis Bet for the Long-Haul - InvestorPlace

December 23, 2021 | benzinga.com

Corporate Cannabis Takeover? Assessing 5 Big Industries Already At The Table - Benzinga - Benzinga

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive APHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aphria and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: TSE
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: TSE:APHA
CUSIP: N/A
CIK: N/A
Web: www.aphria.com
Phone: 844-427-4742
Fax: N/A
Employees: 1,200
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 59.29
Current Ratio: 3.37
Quick Ratio: 1.63

Sales & Book Value

Annual Sales: C$611.06 million
Price / Sales: 8.58
Cash Flow: C$0.74 per share
Price / Cash Flow: 22.40
Book Value: C$4.76 per share
Price / Book: 3.48

Miscellaneous

Outstanding Shares: 316,795,000
Free Float: N/A
Market Cap: C$5.24 billion
Optionable: Optionable
Beta: N/A

Key Executives

Mr. Irwin D. Simon (Age 62)
CEO & Chairman
Comp: $6.54M

Mr. Carl A. Merton
Chief Financial Officer

Dr. Christelle Gedeon L.L.B.
Ph.D., Chief Legal Officer & Corp. Sec.

Mr. James R. Meiers
Chief Operating Officer of Aphria Leamington

Ms. Denise Menikheim Faltischek (Age 48)
Chief Strategy Officer & MD of Aphria Germany
Comp: $562.35k

Mr. John B. Sadler
VP of Investor Relations

Mr. Bernard Yeung
Sr. VP of Sales & Marketing

Mr. Victor Neufeld (Age 67)
Special Advisor

Mr. Cole Cacciavillani (Age 66)
Special Advisor

Mr. Randy Daigneau
Sr. VP of Supply Chain

Key Competitors

View All Competitors

APHA Stock - Frequently Asked Questions

How have APHA shares performed in 2023?: Aphria's stock was trading at C$16.55 at the beginning of 2023. Since then, APHA stock has increased by 0.0% and is now trading at C$16.55.
View the best growth stocks for 2023 here.
What other stocks do shareholders of Aphria own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aphria investors own include Aurora Cannabis (ACB), Canopy Growth (WEED), Aurora Cannabis (ACB), Organigram (OGI), KushCo (KSHB), NVIDIA (NVDA), CannTrust (CTST), Cronos Group (CRON) and Cronos Group (CRON).
What is Aphria's stock symbol?: Aphria trades on the Toronto Stock Exchange (TSX) under the ticker symbol "APHA."
How do I buy shares of Aphria?: Shares of APHA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Aphria's stock price today?: One share of APHA stock can currently be purchased for approximately C$16.55.
How much money does Aphria make?: Aphria (TSE:APHA) has a market capitalization of C$5.24 billion and generates C$611.06 million in revenue each year.
How many employees does Aphria have?: The company employs 1,200 workers across the globe.
How can I contact Aphria?: Aphria's mailing address is 245 Talbot St W Suite 103, LEAMINGTON, ON N8H 1N8, Canada. The official website for the company is www.aphria.com. The company can be reached via phone at 844-427-4742.

This page (TSE:APHA) was last updated on 3/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial